Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90227 | 0.90 | MAPT (0.44) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL89091 | 0.87 | REN (0.46) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL88801 | 0.87 | MAPT (0.47) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL13434188 | 0.86 | MAPT (0.46) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL13091047 | 0.85 | ALDH1A1 (0.47) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL89417 | 0.85 | REN (0.59) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL89089 | 0.85 | MAPT (0.43) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL13434196 | 0.85 | MAPT (0.45) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL89090 | 0.84 | MAPT (0.48) | RENMAPTHPGDTSHRNPSR1 | |
| SCHEMBL13434190 | 0.84 | REN (0.56) | RENMAPTHPGDTSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420491-B1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | REN 1/4885MAPT 1089/4885HPGD 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.